Abstract
The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bissett D., Kerr D. J., Cassidy J., Meredith P., Traugott U., Kaye S. B. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer. 1991 Dec;64(6):1168–1171. doi: 10.1038/bjc.1991.484. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Czejka M. J., Georgopoulos A. High-performance liquid chromatographic determination of adriblastin in human plasma, urine, saliva and liver punctuate by column switching for drug monitoring studies. J Chromatogr. 1988 Jan 22;424(1):182–188. doi: 10.1016/s0378-4347(00)81092-0. [DOI] [PubMed] [Google Scholar]
- Echizen H., Brecht T., Niedergesäss S., Vogelgesang B., Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 1985 Feb;109(2):210–217. doi: 10.1016/0002-8703(85)90585-x. [DOI] [PubMed] [Google Scholar]
- Eichelbaum M., Mikus G., Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984 Apr;17(4):453–458. doi: 10.1111/j.1365-2125.1984.tb02371.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kerr D. J., Graham J., Cummings J., Morrison J. G., Thompson G. G., Brodie M. J., Kaye S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol. 1986;18(3):239–242. doi: 10.1007/BF00273394. [DOI] [PubMed] [Google Scholar]
- Merry S., Flanigan P., Schlick E., Freshney R. I., Kaye S. B. Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer. 1989 Jun;59(6):895–897. doi: 10.1038/bjc.1989.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
- Plumb J. A., Milroy R., Kaye S. B. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol. 1990 Feb 15;39(4):787–792. doi: 10.1016/0006-2952(90)90160-m. [DOI] [PubMed] [Google Scholar]
- Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol. 1984 Nov;18(5):733–740. doi: 10.1111/j.1365-2125.1984.tb02536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]